日付 | 受信時刻 | ニュースソース | 見出し | コード | 企業名 |
2024/12/30 | 21 : 50 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/12/04 | 21 : 30 | Business Wire | Amylyx Pharmaceuticals Announces Pivotal Phase 3 LUCIDITY Trial Design for GLP-1 Receptor Antagonist (Avexitide) in Post-Bariatric Hypoglycemia | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/11/27 | 23 : 00 | Business Wire | Amylyx Pharmaceuticals to Present at the 7th Annual Evercore ISI HealthCONx Conference | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/11/07 | 22 : 22 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/11/07 | 21 : 07 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/11/07 | 21 : 00 | Business Wire | Amylyx Pharmaceuticals Reports Third Quarter 2024 Financial Results | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/11/07 | 09 : 24 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/11/04 | 23 : 00 | Business Wire | Amylyx Pharmaceuticals to Report Third Quarter 2024 Financial Results on November 7, 2024 | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/10/17 | 22 : 12 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/10/17 | 22 : 00 | Business Wire | Amylyx Pharmaceuticals Announces Positive Topline Results from Phase 2 HELIOS Clinical Trial Demonstrating Sustained Improvements with AMX0035 in People Living with Wolfram Syndrome | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/10/15 | 22 : 00 | Business Wire | Amylyx Pharmaceuticals to Host Virtual Webcast to Discuss Topline Results from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on October 17, 2024 | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/10/04 | 04 : 06 | PR Newswire (US) | Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/10/03 | 07 : 53 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/10/03 | 07 : 53 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/10/03 | 07 : 48 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/09/26 | 06 : 56 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/09/17 | 06 : 39 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/09/10 | 05 : 05 | Edgar (US Regulatory) | Form 4 - Statement of changes in beneficial ownership of securities | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/08/28 | 21 : 30 | Business Wire | Amylyx Pharmaceuticals to Participate in Upcoming Investor Conferences | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/08/27 | 07 : 49 | Edgar (US Regulatory) | Form SC 13G - Statement of Beneficial Ownership by Certain Investors | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/08/12 | 22 : 00 | Business Wire | Amylyx Pharmaceuticals Announces Publication of Data Showing the Encouraging Effects of AMX0035 on Cerebrospinal Fluid Biomarkers of Core Alzheimer’s Disease Pathology and Neurodegeneration | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/08/08 | 20 : 14 | Edgar (US Regulatory) | Form 10-Q - Quarterly report [Sections 13 or 15(d)] | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/08/08 | 20 : 09 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/08/08 | 20 : 00 | Business Wire | Amylyx Pharmaceuticals Reports Second Quarter 2024 Financial Results | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/08/05 | 22 : 00 | Business Wire | Amylyx Pharmaceuticals to Report Second Quarter 2024 Financial Results on August 8, 2024 | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/08/02 | 22 : 00 | Business Wire | Amylyx Pharmaceuticals Receives Orphan Drug Designation From the European Commission for AMX0035 for the Treatment of Wolfram Syndrome | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/07/19 | 08 : 00 | PR Newswire (US) | Kuehn Law Encourages Investors of Amylyx Pharmaceuticals, Inc. to Contact Law Firm | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/07/10 | 20 : 09 | Edgar (US Regulatory) | Form 8-K - Current report | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/07/10 | 20 : 00 | Business Wire | Amylyx Pharmaceuticals Announces Acquisition of Phase 3-ready GLP-1 Receptor Antagonist (Avexitide) with FDA Breakthrough Therapy Designation | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |
2024/07/10 | 05 : 01 | Business Wire | Amylyx Pharmaceuticals to Host Conference Call to Discuss the Acquisition of Avexitide | NASDAQ:AMLX | Amylyx Pharmaceuticals Inc |